Marshall Wace
CLYM

Marshall Wace’s Climb Bio CLYM Stock Holding History

Marshall Wace’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.3M Buy
773,123
+469,108
+154% +$2.71M 0.01% 1276
2025
Q4 		$1.22M Buy
304,015
+74,126
+32% +$178K ﹤0.01% 1835
2025
Q3 		$462K Buy
229,889
+193,151
+526% +$359K ﹤0.01% 2263
2025
Q2 		$45.6K Buy
+36,738
New +$45.7K ﹤0.01% 2603

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Marshall Wace's CLYM Position: Q1 2026 in Review

Marshall Wace increased its Climb Bio (CLYM) stake by 154% in Q1 2026, buying an estimated $2.71M and bringing the position to 773,123 shares worth $5.3M. The position accounts for 0.01% of the portfolio, ranked #1276.

Marshall Wace first reported a position in CLYM in Q2 2025 and has held it in 4 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Marshall Wace held 773,123 shares of Climb Bio worth $5.3M as of Q1 2026.
  • Marshall Wace bought 469,108 Climb Bio shares in Q1 2026, an estimated $2.71M.
  • Climb Bio made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1276 holding.
  • Marshall Wace first reported a position in Climb Bio in Q2 2025 and has held it in 4 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.